A drug used with other anticancer drugs to treat systemic anaplastic large cell lymphoma or other peripheral T-cell lymphomas, including angioimmunoblastic T-cell lymphoma, that are CD30 positive and have not been treated with other therapy. It is also used with other anticancer drugs to treat stage III or stage IV classical Hodgkin lymphoma that has not been treated with other therapy. Brentuximab vedotin is also used to treat certain types of Hodgkin lymphoma, anaplastic large cell lymphoma, and mycosis fungoides that were treated with other therapy. It is also being studied in the treatment of other types of cancer. Brentuximab vedotin contains a monoclonal antibody that binds to a protein called CD30, which is found on some lymphoma cells. It also contains an anticancer drug, which may help kill cancer cells. Brentuximab vedotin is a type of antibody-drug conjugate. Also called Adcetris and SGN-35.
Latest research - Brentuximab vedotin